The abstract is read at the publisher; the summary is JClub's.
Classic and trans-signalling by interleukin-6 (IL-6) through membrane-bound IL-6R versus soluble IL-6R (sIL-6R) is linked to distinct disease roles, shaping selective targeting strategies.
- Why it matters: Broad IL-6 pathway blockade has improved autoimmune care but raised safety concerns tied to IL-6’s homeostatic functions, motivating more selective modulation.
- What they did: This Review synthesizes IL-6 signalling biology, including endogenous regulation by sgp130 and trans-signalling control by ADAM17, and compares global versus selective IL-6-targeted therapies.
- The result: Mechanistic and clinical differentiation within the IL-6 pathway is presented as a basis for future drug development aimed at pathway-selective therapeutic effects.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.